Meta Pixel

News and Announcements

How To De-Risk Your Capital Raise

  • Published December 20, 2022 2:50AM UTC
  • Publisher Leila Oliveira
  • Categories Capital Raising Tips

Founder: “I’m already in conversations with five investors, so I wanna see how that goes first before looking for other avenues.” ❌ ❌

Why this is a mistake and how to de-risk your raise:

– Investors keep conversations going to build their pipeline, but it doesn’t mean they will invest in your company. Maybe they invest now. Maybe they will invest in the future. Maybe they will never invest.

– It can take anywhere from 3 to 6 months to see money in the bank. Do you have the cash flow to wait?

– What if after the 6 months they pass? Do you have a plan B?

IT’S WAY TOO RISKY AND STRESSFUL to raise capital like this!

Five ways to de-risk the raise:

1. Don’t rely on a few investors to close your round.

2. Have as many conversations as possible with different investors. Before, during and after the raise.

3. Get an intelligent deal room that provides you insights into the most engaged investors so you can focus your attention on them first. (We use CRIISP- DM if interested)

4. Try to get the faster YES or NO by having all the information well organised and easily accessible

5. Attract investors via presentations, conferences, events, webinars.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now